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Abstract: In recent years, great progress has been made in the field of new therapeutic options 
for hepatitis C virus (HCV) infection. The new direct-acting antiviral agents (DAAs) represent a 
great hope for millions of chronically infected individuals because their use may lead to excel-
lent cure rates with fewer side effects. In Latin America, the high prevalence of HCV genotype 
1 infection and the significant association of Native American ancestry with risk predictive 
single-nucleotide polymorphisms (SNPs) in IFNL4 and ITPA genes highlight the need to 
implement new treatment regimens in these populations. However, the universal accessibility 
to DAAs is still not a reality in the region as their high cost is one of the major, although not 
the only, limiting factors for their broad implementation. Therefore, under these circumstances, 
could the assessment of host genetic markers be a useful tool to prioritize DAA treatment until 
global access to these new drugs can be achieved? This review will summarize the scientific 
evidences and the potential implications of HCV pharmacogenomics in this rapidly evolving 
era of anti-HCV drug development.
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Introduction
The combination of pegylated IFN-alpha plus ribavirin (PEG-IFN/RBV) has been 
the standard of care for chronic hepatitis C virus (HCV) infection since late last cen-
tury. The ultimate goal of this dual therapy is to eradicate HCV infection and thereby 
reduce the risk of progression to HCV-related liver complications. The endpoint of 
HCV treatment is to achieve a sustained virologic response (SVR), which has been 
strongly associated with viral clearance and effectively a cure.1
In addition to its limited efficacy with the most prevalent HCV genotype world-
wide, the PEG-IFN/RBV combination therapy frequently produces intolerability and 
substantial adverse effects. Consequently, the assessment of several viral (genotypes, 
viral load, mutations, etc.) and host (age, gender, degree of liver fibrosis, and alco-
hol consumption, etc.) factors were promptly incorporated in the treatment decision 
 making in order to satisfy the urgent need of prediction of the PEG-IFN/RBV outcome. 
However, despite these influencing determinants, the existence of ethnic variability 
and individual differences observed in the clinical setting could not be thoroughly 
explained; strongly suggesting that host genetic factors might also play a significant 
role in HCV treatment response.1
In 2009–2010, several research groups confirmed the significant association of 
single-nucleotide polymorphisms (SNPs) at IFNL4 and ITPA genes with PEG-IFN/
RBV treatment outcome among HCV-infected patients from around the world.2–7 This 
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breakthrough not only impacted the prognosis and treatment 
of HCV infection, but also allowed to identify patients with 
unfavorable alleles, in whom the response to PEG-IFN/RBV 
treatment would be poor, making them ideal candidates for 
emerging therapies.
Recently, the development of direct-acting antiviral agents 
(DAAs) represents an outstanding progress in the field of 
therapeutic options for HCV chronic infection, which have 
improved the chance of cure and ameliorated the prognosis 
of the disease. These new antiviral agents offer a range of 
advantages compared with their predecessors, have multig-
enotypic activity, shorter schemes, fewer side effects, and 
higher cure rates, including for those in advanced stages of 
infection.8,9 In this current scenario, pharmacogenetics seems 
to have a reduced usefulness. However, the universal avail-
ability of these new treatment regimens – with DAAs alone 
or in combination with other DAAs or PEG-IFN/RBV – is 
still not a reality, particularly for HCV patients in the public 
health system of Latin American countries.10–12
In this review, we summarize the scientific evidences 
and the potential implications of HCV pharmacogenomics 
in this rapidly evolving era of anti-HCV drug development.
HCV in Latin America: burden 
of infection and accessibility to 
treatment
The burden of HCV infection is expected to increase around 
the world and Latin America is no exception to this scenario.13
In recent years, different studies have addressed the epi-
demiology of chronic HCV infection in Latin America.14,15 
Nonetheless, there is still a paucity of information in the 
region, since most of the available data come from spontane-
ous demand studies in specific groups, which do not faithfully 
represent the prevalence in the general population.16,17
Despite this limitation, it is estimated an average preva-
lence rate for HCV of 2.0%±0.25% in the adult population, 
which represents at least 10 million individuals who are anti-
HCV positive in Latin America.14,17,18 On the whole, Latin 
America has the lowest HCV prevalence compared with others 
regions around the world. However, these rates vary among 
countries and even in different areas within the same country.
Most of the HCV-infected individuals in Latin America 
are in Brazil with more than 2.5 million cases, being among 
the 10 countries with more cases worldwide.17,19,20 The second 
largest epidemiologic burden due to HCV is found in Mexico 
with 1.6 million cases. The third and fourth place is held by 
Colombia and Argentina with ~690,000 and 342,000 cases, 
respectively.17,21,22
There is a consensus that most cases occur among people 
aged 55 years and older.23,24 Likewise, it was estimated that 
the peak incidence occurred in the mid to late 90s and pre-
dicted a slow decline in the prevalence for the next decades 
as a result of prophylactic measures and the effectiveness of 
current antiviral agents.17,25 However, due to the fact that 75% 
of HCV infections evolve into chronicity, the consequences 
of the natural course of the disease are observed decades after 
the infection; resulting in future high costs of monitoring, hos-
pitalization, or transplantation for health care systems.17,18,20
As regards HCV genotypes, in Latin America >50% 
of the cases are caused by genotype 1, followed by 2 or 3 
depending on the country.26 This poses a drawback, because 
the overall cure rate of patients infected with genotype 1 
treated with PEG-IFN-α/RBV is low, being ~40%–50%,1 
which represents high costs to governments without com-
parable effectiveness.
In addition, <2% of HCV chronically infected individuals 
have access to treatment.18,24,25 Particularly, access to standard 
PEG-IFN/RBV therapy is extremely limited in underserved 
populations without affiliation to health care systems, which 
are paradoxically the neediest.
In recent years, several DAAs have been developed. These 
new antiviral agents represent a great hope for millions of 
chronically infected individuals because their use may lead 
to excellent cure rates. Nevertheless, the high cost of these 
new drugs is one of the major, although not the only, limit-
ing factors for its broad implementation, mainly in low- or 
lower-middle income countries (Figure 1).10,11
In Latin America, the public health care systems often 
show fragmented schemes mostly concentrated on specific 
sectors of society. However, in many cases, macroeconomic 
troubles, political obstruction, and inadequate management led 
to pay-as-you-go in practice. Although HCV treatment-related 
costs are mostly responsibility of the public health system, in 
50% of cases patients paid treatments from their own pocket, 
25% were paid by private insurance, and only 25% treatments 
were afforded by the public health sector. Moreover, >95% of 
patients infected with viral hepatitis belong to a low-income 
population and/or are uninsured, and they cannot afford to pay 
the current market prices of DAAs (Figure 1).27
In addition, viral hepatitis is not considered to be a severe 
health problem by health officials in Latin America, which in 
turn have manifested ignorance or reluctance toward a state 
program of detection or treatment of this disease. The lack of 
precise epidemiologic information about HCV infection is an 
ongoing difficulty, which translates into the lack of precision 
of who and how many people are infected and primary risk 
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factors involved.18 Another limiting factor is the corruption 
and slow bureaucracy to introduce these drugs; even though 
the pharmaceutical industry has declared a responsibility to 
create agreements based on the economy of each country for 
the marketing of the antiviral drugs (Figure 1).28
At present, the first-wave of NS3/NS4 inhibitors (telapre-
vir and boceprevir), are the most available DAAs in Latin 
America.28–30 However, these are no longer used due to their 
limitations compared with the second-generation inhibitors 
and those targeted against other HCV genes.31
Therefore, the strategy in the region is to use second-
generation DAAs in those countries, where available, and 
delay patient treatment until arrival in those countries, where 
they are not.28
In recent years, simeprevir, daclatasvir, and sofosbuvir 
have been or are being approved and are currently available 
in Argentina and Brazil.12,28,30 At the moment, the prescrip-
tion is restricted to older patients with unequivocal signs of 
liver damage.
In 2014, Gilead announced a voluntary license agreement 
with several Indian drug manufacturers that allow these com-
panies to produce and sell generic versions of sofosbuvir and 
ledipasvir. Bolivia is the only country in the region benefited 
from this measure.
In order to secure some price discounts on these high-
cost treatments The Union of South American Nations has 
proposed the creation of a fund to negotiate centralized 
purchases of the HCV treatments and began the process of 
joint purchase of DAAs through the Pan American Health 
Organization Strategic Fund last year.
HCV pharmacogenomics
In 2009, four independent genome-wide association studies 
(GWAS) reached the same and definitive conclusion: poly-
morphisms rs12979860C/T and rs8099917G/T in or near the 
IL28B gene, also known as IFN lambda 3 (IFN-λ3 or IFNL3) 
but as the discovery of IFNL4 is now classified as an IFNL4 
SNP, significantly affect the spontaneous clearance of acute 
HCV infection and the response to PEG-IFN/RBV therapy 
(Table 1).2–5 The two GWAS-identified SNPs, rs12979860 
and rs8099917 are in low to strong linkage disequilibrium, 
based on specific populations tested, and both markers were 
used for predicting response to PEG-IFN and RBV therapy.4,32
Prokunina-Olsson et al identified a transiently induced 
region in a new gene member, denoted IFNL4 gene, which 
shows a dinucleotide variant (rs368234815 or ss469415590 
TT/ΔG). This novel interferon is produced only in carriers of 
ΔG allele carriers and has been related to unsuccessful viral 
clearance in the presence or absence of treatment (Table 1).33 
IFNL4 variants rs368234815 and rs12979860 are in high link-
age disequilibrium and provide similar predictive information 
in Asians, and comparable information in Europeans. How-
ever, in individuals of African ancestry there is a lower linkage 
disequilibrium between these markers and rs368234815 is 
significantly more informative than rs12979860.33–35
Since then, various studies have verified the impact of 
IFNL4 on HCV infection and treatment outcome across 
different HCV genotypes,32,36,37 and in individuals coinfected 
with HIV.38 Although on-treatment predictors are more 
significantly associated with therapeutic success,39 the viral 
genotype and the rs368234815 IFNL4 SNP are considered 
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Political
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Figure 1 Limiting factors for the global access to DAAs in Latin America.
Abbreviations: DAAs, direct-acting antiviral agents; HCV, hepatitis C virus.
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the most powerful pretreatment predictors of response to 
PEG-IFN/RBV therapy.40
For treatment-naïve patients with genotype 1 infection 
who are treated with protease inhibitor combinations, IFNL4 
genotypes predicts response and also eligible for the shorter 
durations of therapy.41 Although all IFNL4 genotypes have 
improved response rates as compared with patients treated 
with PEG-IFN/RBV only, patients with the favorable IFNL4 
genotype still have higher response rates with the protease 
inhibitor combination in treatment-naïve patients, and these 
response rates may guide patients and clinicians in their 
treatment decisions.
Second-wave DAAs, such as sofosbuvir, simeprevir, 
and daclatasvir, can be administered in combination with 
PEG-IFN/RBV as triple therapy for patients with HCV 
genotype 1. In these highly potent regimens, cirrhosis and 
IFNL4 genotype are still predictors of response.42,43 In con-
trast, although host genetic factors have a lesser impact on 
treatment response in IFN- and RBV-free regimens, recent 
studies have reported that the IFNL4 variants can influence 
the risk of antiviral resistance.44–46
In addition, recent reports have demonstrated that poly-
morphisms at other genes could also be related to the risk 
of PEG-IFN/RBV treatment withdrawal due to drug-related 
adverse effects.47–49 In this regard, one of the most important 
treatment-limiting toxicities is RBV-induced hemolytic ane-
mia, which has been linked to two functional polymorphisms 
in the ITPA gene – a missense variant in exon 2 (rs1127354) 
and a splice-altering SNP in intron 2 (rs7270101) – and to 
a nonfunctional one (rs6051702).47,48 These variants induce 
an inosine triphosphate pyrophosphohydrolase deficiency, 
a benign red cell enzymopathy associated with a protective 
effect against RBV-induced hemolytic anemia in HCV-
infected patients.47–50
It is important to highlight that ITPA gene polymorphisms 
are not related to treatment response but to the prediction of 
RBV-induced hemolytic anemia and thus, the need of dose-
reduction or even treatment withdrawal (Table 1).49,51
Although new therapies with first-wave protease inhibi-
tors improved SVR, they also increased side effects, such as 
rash and anemia. Several studies highlighted the ITPA role 
in predicting anemia in these new regimens.50,52 In the case of 
second-wave protease (such as simeprevir) and polymerase 
inhibitors (such as sofosbuvir), effectiveness have been fur-
ther increased and adverse effects have been considerably 
reduced. Most of these regimens are RBV-free and they are 
already approved or undergoing phases II and III studies in 
different countries.42
Genetic ancestry influences HCV 
pharmacogenomics in Latin 
America
Along the end of the Pleistocene (11,700 years ago), a limited 
number of immigrants arrived to the American continent 
entering from the eastern edge of Siberia by crossing the Ber-
ing Strait. Immigrants explored the territories, some settled, 
others keep moving south and eastward within the American 
continent. After a long period of isolation, the continent was 
explored by Europeans conquerors who – after submitting 
the aboriginals – started the colonization process. The major 
transatlantic migratory contribution to Latin America was 
provided by the Iberians who colonized the major extension 
of the continent. During the late sixteenth and beginning of 
the seventeenth century, European colonists introduced West 
and East Sub-Saharan Africans as working forces. Throughout 
the Americas, even within the same country, historical differ-
ences in pattern of settlement and migration have resulted in 
a wide range of genetic variation reflecting complex admixed 
events involving actors of different ancestral background.53
Regarding the maternal lineage, in general, it can be 
observed a high proportion of Native American maternal 
ancestry, belonging to haplogroups A–D of the mitochondrial 
Table 1 Genetic factors related to HCV pharmacogenomics
NCBI dbSNP id Location Alleles Associated with References
rs368234815 IFNL4 TT Spontaneous and/or PEG-IFN/RBV treatment-induced HCV clearance 33–35, 40, 43
ΔG HCV persistence and/or PEG-IFN/RBV treatment failure
rs12979860 IFNL4 C Spontaneous and/or PEG-IFN/RBV treatment-induced HCV clearance 2–5, 32, 35–42
T HCV persistence and/or PEG-IFN/RBV treatment failure
rs8099917 IFNL4 T Spontaneous and/or PEG-IFN/RBV treatment-induced HCV clearance 2–5, 32
G HCV persistence and/or PEG-IFN/RBV treatment failure
rs1127354 ITPA A Low risk of RBV-induced hemolytic anemia 47–52
C High risk of RBV-induced hemolytic anemia
rs7270101 ITPA C Low risk of RBV-induced hemolytic anemia 47–52
A High risk of RBV-induced hemolytic anemia
Abbreviations: HCV, hepatitis C virus; PEG-IFN/RBV, pegylated IFN-alpha plus ribavirin; SNP, single-nucleotide polymorphism.
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DNA. Certainly, the different proportion found in each coun-
try will depend on its own colonization history.54–58
In contrast, the paternal lineage depicts a different 
scenario. In this case, the European contribution is mainly 
represented by the R1b haplogroup in the Y-chromosome.55,59 
The proportion of the Native American haplogroup Q1a3a, 
depends on the survival of the Native American males, given 
their killing carried out by Europeans during the conquest.
Although both male and maternal lineages offer an idea 
of the different parental populations contributions, autosomal 
ancestry-informative markers quantify the genetic admixture 
extent.55 In general, urban towns of Argentina, Mexico, Chile, 
Colombia, Uruguay, and South of Brazil showed that >55% 
of the global ancestry belongs to European contribution 
followed by Native American and <10% of African contri-
bution.55,60,61 Instead, rural Mexico and urban populations in 
Peru and Bolivia showed the major contribution of Native 
American ancestry in part due to the high population density 
of aboriginal in the region at the moment of the conquest.60–63
Latin America experienced one of the largest admixture 
processes in a reduced span of time of just 20 generations. 
These circumstances have important implications for the 
expected relative proportion of ancestral genetic makeup with 
potential effects on disease susceptibilities, ability to metabo-
lize therapeutic compounds demonstrating the need to genetic 
ancestry determination in future genetic association studies.
Several epidemiologic studies have demonstrated that 
the allele frequencies of IFNL4 and ITPA predictive SNPs 
exhibit variations among worldwide populations with differ-
ent ancestry background.32,64 However, these data obtained 
from well-defined ethnic groups cannot be extrapolated to 
genetically admixed and multiethnic populations, such as 
those in Latin America.65
Several research groups have confirmed the significant 
association of IFNL4 and ITPA SNPs with PEG-IFN/RBV 
treatment outcome among HCV-infected Latin American 
patients.66–72 Meanwhile, in the general population of the 
region, these predictive polymorphisms exhibit extremely 
variable frequencies.73,74 Nevertheless, in order to avoid draw-
ing false conclusions, it is important to highlight that the high 
heterogeneity of Latin American populations was not taken 
into consideration by these groups and, therefore, the analysis 
of genetic ancestry was not carried out in these studies.65
The population diversity in Latin American, with 
trihybrid ancestral roots and five centuries of admixture, 
cannot be detected by color/race self-identification and 
should be described by molecular approaches. In this 
regard, recent studies have concluded that the distribution 
of these SNPs is closely related to the genetic ancestry in 
Latin America.35,75–78 A study carried out among 2150 non-
HCV-infected individuals from Argentina, Peru, Bolivia, 
and Paraguay, showed that the frequency of IFNL4 and 
ITPA SNPs exhibits a specific geographical pattern of dis-
tribution, even within the same country (Figures 2–4), and 
is closely related to the maternal and paternal ancestry of 
the population (Figures 5 and 6). In fact, the prevalence of 
favorable genotypes is significantly higher in populations 
with European ethnicity, intermediate in admixed individu-
als, and the lowest in populations with Native American 
ancestry background.75,76 These findings were confirmed 
in western Mexico, where the TT/GG/ΔG risk haplotype in 
the IFNL4 gene predominates in Native Americans when 
compared with the “Mestizos” (admixed) group.35 With 
respect to the association of these SNPs with HCV clearance 
in the presence or absence of PEG-IFN/RBV treatment, the 
protective alleles were more frequently observed among 
admixed Mexicans with spontaneous clearance of HCV 
infection.35 Moreover, studies carried out among HCV 
chronic patients from Brazil revealed that IFNL4 polymor-
phisms predict therapy response in patients with admixed 
ancestry.77,78 Interestingly, this association is influenced 
by ancestry; being the African genetic contribution higher 
among the nonresponder patients with the rs12979860 TT 
genotype, whereas the Native American and European 
genetic ancestry prevail in the SVR group.77
Implications in the era of DAAs
Several studies carried out in different geographical scenarios 
have shown that DAAs implementation is cost-effectiveness 
per person treated, but pent-up demand for treatment will cre-
ate challenges for financing.10,79,80 Cost-effectiveness studies 
have not been conducted in Latin America and, therefore, the 
implication that these new therapies might have in health-
related economics is unpredictable and its relevance in HCV 
control will probably remain negligible as long as access to 
the therapy cannot be expanded.81
In this region, the high rate of infections with HCV geno-
type 1 and the high frequency in Native American populations 
of the TT genotype of IFNL4 SNP rs12979860 – markers 
associated with poor response to PEG-IFN/RBV therapy in 
both cases35,75–78 – support the hypothesis that the implemen-
tation of IFN-free regimen should be beneficial in terms of 
cost–benefit. However, before or until global availability to 
DAAs is achieved, the identification of host predictive mark-
ers of antiviral therapy outcome could still be useful, as it 
will help prioritize DAA access.
Pharmacogenomics and Personalized Medicine 2017:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
84
Trinks et al
Furthermore, it is important to highlight that IFNL4 not only 
plays an important role on establishing the likelihood of treat-
ment response with PEG-IFN/RBV and to triple (single DAA 
plus PEG-IFN/RBV) and quadruple (two DAAs plus PEG-IFN/
RBV) regimens,41,42 but also exert, an effect on the early viral 
kinetics in HCV chronic patients receiving the emerging IFN 
and RBV-free schemes.82,83 In addition, recent studies have 
reported that the presence of resistance variants, number, and 
Figure 2 IFNL4 SNP rs12979860.
Notes: Prevalence of the favorable (CC) and risk (CT/TT) genotypes of IFNL4 SNP rs12979860 in Bolivia (A, n=185), Peru (B, n=76), Paraguay (C, n=98), and the different 
geographic regions of Argentina: Central (D, n=991), Northwestern (E, n=250), Northeastern (F, n=260), Western (G, n=175), and Southern (H, n=115) areas. ap<0.05 when 
comparing samples from the Central region of Argentina with those from the Northeastern and Northwestern regions, Peruvians and Paraguayans; bp<0.0001 when comparing 
samples from the Central region of Argentina with Bolivians. Copyright ©2014. Nature Publishing Group. Adapted from Trinks J, Hulaniuk ML, Caputo M, et al. Distribution of 
genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population. Pharmacogenomics J. 2014;14(6):549–554.75 Adapted 
with permission from Trinks J, Hulaniuk ML, Caputo M, et al. Distribución de polimorfismos de nucleótido simple (SNPs) predictores de la respuesta al tratamiento antiviral en 
la infección crónica por el virus de la hepatitis C (HCV) en las distintas regiones geográficas de Argentina [Distribution of singlenucleotide polymorphisms (SNPs) predictive of 
antiviral treatment response in hepatitis C virus (HCV) chronic infection in different geographic regions in Argentina]. Medicina (B Aires). 2014;74 (Suppl 3):S117–S118. Spanish.76
Abbreviation: SNP, single-nucleotide polymorphism.
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Figure 3 ITPA SNP rs1127354.
Notes: Prevalence of the favorable (CA/AA) and risk (CC) genotypes of ITPA SNP rs1127354 in Bolivia (A, n=185), Peru (B, n=76), Paraguay (C, n=98), and the different 
geographic regions of Argentina: Central (D, n=991), Northwestern (E, n=250), Northeastern (F, n=260), Western (G, n=175), and Southern (H, n=115) areas. ap<0.05 
when comparing samples from the Central region of Argentina with Peruvians and Paraguayans; bp<0.001 when comparing samples from the Central region of Argentina with 
those from the Northwestern region; cp<0.0001 when comparing samples from the Central region of Argentina with Bolivians. Copyright ©2014. Nature Publishing Group. 
Adapted from Trinks J, Hulaniuk ML, Caputo M, et al. Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and 
admixed population. Pharmacogenomics J. 2014;14(6):549–554.75 Adapted with permission from Trinks J, Hulaniuk ML, Caputo M, et al. Distribución de polimorfismos de 
nucleótido simple (SNPs) predictores de la respuesta al tratamiento antiviral en la infección crónica por el virus de la hepatitis C (HCV) en las distintas regiones geográficas 
de Argentina [Distribution of singlenucleotide polymorphisms (SNPs) predictive of antiviral treatment response in hepatitis C virus (HCV) chronic infection in different 
geographic regions in Argentina]. Medicina (B Aires). 2014;74 (Suppl 3):S117–S118. Spanish.76
Abbreviations: ITPA, inosine triphosphatase; SNP, single-nucleotide polymorphism.
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diversity of NS5A quasispecies is strongly associated with 
favorable IFNL4 genotypes, probably as a consequence of the 
fact that patients with the beneficial genotypes induce a more 
efficient antiviral response that results either in viral clearance 
or selection for viral adaptations. This regulating influence of 
host genetic factors on the nature of the viral quasispecies could 
be of clinical interest for consideration of IFN-free treatment 
options for patients with known IFNL4 status.44–46
In Latin America, pharmacogenomics could still provide an 
instrument to optimize HCV management, taking into account 
ethnic differences and explaining the variability in treatment 
response. As a consequence, HCV pharmacogenetics will still 
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Notes: Prevalence of the favorable (AC/CC) and risk (AA) genotypes of ITPA SNP rs7270101 in Bolivia (A, n=185), Peru (B, n=76), Paraguay (C, n=98), and the different 
geographic regions of Argentina: Central (D, n=991), Northwestern (E, n=250), Northeastern (F, n=260), Western (G, n=175), and Southern (H, n=115) areas. ap<0.05 
when comparing samples from the Central region of Argentina with those from the Northeastern region; bp<0.0001 when comparing samples from the Central region of 
Argentina with those from the Northwestern region, Bolivians, and Peruvians. Copyright ©2014. Nature Publishing Group. Adapted from Trinks J, Hulaniuk ML, Caputo M, 
et al. Distribution of genetic polymorphisms associated with hepatitis C virus (HCV) antiviral response in a multiethnic and admixed population. Pharmacogenomics J. 
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represent an ongoing challenge for Latin American clinicians 
and hepatologists in the treatment decision making.
Conclusion
In the last 5 years, resonant advances related to infection by 
hepatitis C have been obtained, making conceivable that HCV 
chronic infection will soon become an easier-to-treat disease.
Nowadays, HCV treatment varies throughout the world 
because some regions have access to the new DAAs, whereas 
other areas have access only to PEG-IFN/RBV. Although 
the high prevalence of HCV genotype 1 in Latin America 
and unfavorable predictive SNPs among Native Americans 
highlight the need to implement new treatment regimens 
in these populations, the universal accessibility to DAAs 
is still not a reality in the region. Therefore, the PEG-IFN/
RBV treatment will still be the only therapy available until 
the costs of the new drugs have decreased and their access 
to HCV patients has globalized.
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In this review, the report of several studies concerning phar-
macogenetic factors related to HCV treatment in Latin America 
might help to adjust the regional treatment policies for HCV 
infection based on greater certainty in studies with populations 
with such genetic characteristics. They also confirm that, in this 
vast territory, there are populations with different genotypic 
characteristics that might, depending on the situation, require 
different approaches to treatment and research.
In this perspective, the assessment of host genetic mark-
ers in all HCV patients to predict response and evaluate 
the risk–benefit of available therapies might be useful to 
improve strategies and fight the infection and could be a 
cost-effective means of risk stratification in the developing 
countries. In this regard, several scientific societies and 
studies have declared that, until global access to DAAs is 
guaranteed, treatment-naïve patients exhibiting favorable 
clinical, genetic, and virologic profiles could still benefit 
with the PEG-IFN/RBV regimen; thus restricting the use 
of newer and expensive treatment schemes for “difficult to 
treat” patients.22,29,41,70,84–87
In future decades, it is expected that, particularly in the 
developing countries, the burden of HCV disease increases 
due to the absence of an effective vaccine, the insufficient 
amount of public awareness, and preventive measures.13,14,17 
Therefore, regardless of the great therapeutic advances, 
improvements in HCV surveillance, epidemiologic map-
ping, testing, prevention, and therapy are urgently needed. 
The challenge now is to overcome barriers to HCV testing 
and improve access to antiviral treatment in the low- and 
middle-income countries. Guarantee access to medicines 
is a joint responsibility of governments, multilateral 
agencies, and nongovernmental organizations. But also, 
pharmaceutical companies should be a part of the solution. 
Eventually, the global HCV control will be achieved with 
the joint efforts of governments, researchers, and public 
health workers.
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